Niva Bupa Health Insurance Company Limited has informed the Exchange about Resignation of Director/KMP/SMP
NIVABUPA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.0 pts more than Nifty Smallcap 250 and 3.0 pts more than its General Insurance peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Niva Bupa's Board meeting on May 8, 2026 resulted in multiple changes. Two Non-Executive Directors—Ms. Penelope Ruth Dudley and Mr. Carlos Antonio Jaureguizar Ruiz-Jarabo—resigned citing insufficient time due to other professional commitments, effective close of business on May 8, 2026. In parallel, the Board appointed Mr. Christopher Patrick Carroll (CEO of Bupa Global, India & UK) and Ms. Siobhan Djihan Moynihan (CFO of Bupa Global, India & UK) as Additional Non-Executive Directors, effective May 15, 2026, subject to shareholder approval within 3 months. Additionally, Mr. Ankur Kharbanda was elevated from Executive Director and Chief Business Officer to Executive Director and Deputy Chief Executive Officer, effective May 8, 2026. The Board also approved granting 12,251,268 ESOPs (worth approximately ₹887.6 million at ₹72.45 per option) to eligible employees under ESOP Scheme 2024, compliant with SEBI regulations.
The resignation of two Non-Executive Directors and their replacement with two senior Bupa executives (CEO and CFO of Bupa Global) suggests a possible consolidation of parent company oversight on the board. The Deputy CEO elevation indicates internal succession planning. The large ESOP grant may help retain talent but will dilute earnings per share upon exercise.